Cancer clinical trials最新文献_第3页

Cystosarcoma phyllodes. Diagnosis and management. Cystosarcoma叶状柄。诊断和管理。

Cancer clinical trials Pub Date : 1981-01-01

J C Rosenfeld, D A DeLaurentis, H Lerner

引用次数: 0

A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancer. 局限性小细胞肺癌术前胸椎预防性全脑放射治疗一例。

Cancer clinical trials Pub Date : 1981-01-01

R T Eagan, S Frytak, R E Lee, E T Creagan, J N Ingle, W C Nichols

引用次数: 0

Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum. WR2721联合放疗、烷基化剂环磷酰胺和顺铂的一期临床试验。

Cancer clinical trials Pub Date : 1981-01-01

M M Kligerman, A L Blumberg, J H Glick, D F Nelson, D Glover, J M Yuhas, H I Amols, R L Goodman

{"title":"Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.","authors":"M M Kligerman, A L Blumberg, J H Glick, D F Nelson, D Glover, J M Yuhas, H I Amols, R L Goodman","doi":"","DOIUrl":"","url":null,"abstract":"Three phase I trials of the radioprotector S-2-(3-aminopropylamino) ethylphosphorothioic acid (WR2721) have accessed 60 patients. Study 1 is devised to determine the maximum tolerated dose (MTD) of a single dose of the protector 15 to 30 minutes before a single radiation treatment of a size used routinely in palliative management. Study 2 plans to determine the MTD for up to 15 daily doses of the drug over 3 weeks during palliative radiotherapy. Also, the multipe-dose study will establish the MTD before palliative irradiation for fewer than five fractions a week. Study 3 uses the existing single-dose MTD determined in Study 1 as pretreatment 15 to 30 minutes before cyclophosphamide or cis-platinum. Toxic symptoms include emesis, hypotension, hypertension, somnolence, and sneezing. Only one serious episode of hypotension, considered idiosyncratic, and one instance of moderate to severe vomiting have occurred. Forty-one patients have been entered in Study 1 and a dose of 600 mg/m2 has been reached. The next step is to proceed to the planned highest level of 740 mg/m2. Of five patients in the multiple-dose study, one has been given, without toxicity, WR2721 at the level of 100 mg/m2 for 15 fractions over 3 weeks. Fourteen patients are accessed to the alkylating agent study. Using protector doses of 450 mg/m2, a cyclophosphamide level of 1500 mg/m2 has been accomplished. However, two of three patients who received 450 mg/m2 of WR2721 before 120 mg/m2 of cis-platinum have shown moderate elevation of the serum creatinine, both of which returned to normal.","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 4","pages":"469-74"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17337454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zinostatin and doxorubicin. A combination phase I study. 唑他汀和阿霉素。第一阶段的联合研究。

Cancer clinical trials Pub Date : 1981-01-01

B F Issell, S J Ginsberg, R L Comis

引用次数: 0

A clinical trial of pyrazofurin in combination with 5-azacytidine in acute adult nonlymphocytic leukemia. 吡唑呋喃联合5-氮杂胞苷治疗急性成人非淋巴细胞白血病的临床研究。

Cancer clinical trials Pub Date : 1981-01-01

D A Van Echo, D F Chiuten, S Markus, P H Wiernik

{"title":"A clinical trial of pyrazofurin in combination with 5-azacytidine in acute adult nonlymphocytic leukemia.","authors":"D A Van Echo, D F Chiuten, S Markus, P H Wiernik","doi":"","DOIUrl":"","url":null,"abstract":"Twenty adult patients with relapsed acute nonlymphocytic leukemia were given intravenously the combination of pyrazofurin (PF) 7.5-30 mg/m2 x 1 on day 1 plus 5-azacytidine (AZA) 150-250 mg/m2/d in three divided doses for 5 days. Four patients are early deaths secondary to infection or hemorrhage and are invaluable for response. Three patients achieved a response (two patients had a CR, the third patient had a CR, relapsed, and then a PR). Duration of response was short (41-94 days). Hematologic toxicity was universal and similar at al dose ranges studied. The median pretreatment WBC and platelet counts were 500 and 32,000/microliter, respectively, and the nadirs were 500 and 15,000/microliter. Recovery only occurred in those patients who achieved a response. Nonhematologic toxicity consisted of skin rash (100% of the courses), mucositis (60%), myalgia (93%), nausea and vomiting (83%), and hypotension (47%). In conclusion, although there is interesting preclinical data to suggest that the combination of PF and AZA has synergistic cytotoxicity on leukemic cells, this human clinical trial demonstrates that the combination has significantly more nonhematologic toxicity than AZA alone and no therapeutic advantage over treatment with AZA alone.","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"129-33"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17232163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alternating non-cross-resistant drug combinations in the treatment of metastatic small-cell carcinoma of the lung. 交替非交叉耐药组合治疗转移性肺小细胞癌。

Cancer clinical trials Pub Date : 1981-01-01

S Krauss, S Lowenbraun, A Bartolucci, R Buchanan, R Birch

{"title":"Alternating non-cross-resistant drug combinations in the treatment of metastatic small-cell carcinoma of the lung.","authors":"S Krauss, S Lowenbraun, A Bartolucci, R Buchanan, R Birch","doi":"","DOIUrl":"","url":null,"abstract":"In a randomized trial of the Southeastern Cancer Study Group, patients with metastatic small-cell lung carcinoma were treated with a combination of cyclophosphamide (500 mg/m2 I.V.), Adriamycin (50 mg/m2 I.V.), DTIC (250 mg/m2 I.V.), and vincristine (1 mg/m2 I.V.) every 4 weeks for three cycles. Complete and partial responders to this induction regimen were then randomized to receive either the same combination every 4 weeks for an additional six cycles versus a non-cross-resistant drug combination of BCNU (100 mg/m2 I.V.), procarbazine (100 mg/m2 p.o. daily x 10 days), methotrexate (25 mg/m2 I.V.), and vinblastine (5 mg/m2 I.V.) every 4 weeks for six cycles versus alternating treatments with the two regimens for a total of six cycles of therapy. Patients who were less than good responders received six cycles of the non-cross-resistant drug combination. Of 202 evaluable patients, 40% responded (complete + partial responses) to induction; the complete response rate for the whole group was low (14%). Patients randomized to the BPMV combination, or crossed over to it, failed to improve upon their response to induction. Patients who responded to induction had a median survival of 41 weeks versus 20.6 weeks for the nonresponders, p less than 0.001. Performance status greater than or equal to 60%, and absence of prior radiotherapy were associated with improved survival (30 and 31.5 weeks, respectively). The toxicity of these regimens was acceptable. Failure to improve on results of our earlier protocol were probably due to the long (weeks) interval between treatments, inclusion of a relatively inactive but toxic drug (DTIC) in the induction combination which limited doses of the more active agents, and the use of a non-cross-resistant drug regimen which was inactive.","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"147-53"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17327545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase II study of hexamethylmelamine for disseminated prostatic carcinoma. 六甲基三聚氰胺治疗播散性前列腺癌的II期研究。

Cancer clinical trials Pub Date : 1981-01-01

A Drelichman, R Brownlee, M Al-Sarraf

引用次数: 0

Misonidazole dose and tumor level relationships. Effects of individual variation in rate of misonidazole metabolism and absorption from the gastrointestinal tract. 米索硝唑剂量与肿瘤水平的关系。米索硝唑代谢和胃肠道吸收速率个体差异的影响。

Cancer clinical trials Pub Date : 1981-01-01

J M Strong, J G Schwade, D Gangji, D D Shoemaker, D K Upton

引用次数: 0

Phase I-II trial of methyl-GAG in advanced colon cancer. a Southwest Oncology Group pilot study. 甲基gag治疗晚期结肠癌的I-II期临床试验。西南肿瘤小组的一项试点研究

Cancer clinical trials Pub Date : 1981-01-01

J W Myers, W A Knight, R B Livingston, C Fabian, J Costanzi